Sunshine Act

11.8.2011 Fair-Market Value

Physician’s Conflict of Interest in Spotlight Again after BMJ Study Published

By Ryan McGuire,Senior Research Analyst A study published in the British Medical Journal has received a lot of attention lately. It highlighted the prevalence of financial conflicts of interest (COI) for researchers sitting on 14 specific guideline-setting...
 

7.27.2011 Clinical Development

Sunshine Act Presents Uncertainty for Clinical Development

The sunshine provision of the landmark U.S. healthcare law passed in 2010 requires that drug and device manufacturers report all gifts and payments exceeding $10 in value. While the law seems clear for consulting fees, it becomes quite murky when discussing clinical...
 

7.22.2011 Medical Affairs

Hard Limits on Thought Leader Compensation Employed Less Often by Pharma

As compliance and medical affairs teams prepare for the Sunshine Act, they are relying less on exact compensation limits for key opinion leaders.  “KOL Fair-Market Value and Aggregate Spend: Documentation, Tracking and the Sunshine Act” found that only 35...
 

7.11.2011 Fair-Market Value

What Pharma and Biotech Companies Are Currently Paying European Key Opinion Leaders

Cutting Edge Information’s new research on European fair-market value benchmarks found that drug manufacturers spend between €153 and €283 for a typical key opinion leader (KOL) engagement. Payments vary by company size; biotechnology companies pay European...
 

6.14.2011 Fair-Market Value

Key Opinion Leader Payments Drop by 50%

Average physician fee schedules for hourly payments to KOLs have fallen each year since 2006, finds Cutting Edge Information Drug and device manufacturers have responded to criticism over physician payments by decreasing their average level of compensation by...
 

6.1.2011 Fair-Market Value

Sunshine Act Impacts Drug Companies’ Promotional Activities

Although the Sunshine Act requires disclosures for grants and other funding of medical research, the majority of payment categories are focused on promotional engagements. A new report from Cutting Edge Information finds that drug manufacturers are feeling the...
 

4.12.2011 KOL Management

Drug Companies Embrace Proactive Approach to Transparency

Cutting Edge Information Declares Series of New Disclosure Laws Not Yet Over The wave of pharmaceutical transparency laws has not yet crested, according to research from Cutting Edge Information, and drug companies are responding with steps to reveal their compensation...
 

2.8.2011 KOL Management

Transparency Could Hamper Thought Leader Relationships

As drug companies face requirements to report all spending on physician-related activity, relationships between thought leaders and drug manufacturers are feeling the strain. Aside from individual state laws requiring companies to report payments to physicians,...
 

1.16.2011 KOL Management

Sunshine Act is Now Law: Will KOL Relationships be Impacted?

The Sunshine Act, originally drafted in 2007, has been made law as part of the Patient Protection and Affordable Care Act. What passed was really a revised version of the original, of course, but the Sunshine Act is now the law of the land, and that will impact...